SCHEMBL4120324

SCHEMBL4120324

CCOC1CCN(c2c(-c3ccccc3Cl)cnc3c(C(=O)O)cnn23)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.39
SMO Q99835 2/20 0.37
MAPT P10636 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
NFKB1 P19838 2/20 0.36
RAB9A P51151 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
HCRTR2 O43614 1/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 3/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35
STAT1 P42224 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4120972 0.92 KDM4E (0.44) GPR119MAPTSMN1; SMN2NPC1NFKB1
SCHEMBL2085113 0.86 KMT2A (0.45) MAPTSMN1; SMN2NPC1RAB9ACNR2
SCHEMBL2086791 0.82 KDM4E (0.46) GPR119MAPTSMN1; SMN2NPC1NFKB1
SCHEMBL4121602 0.82 KDM4E (0.46) GPR119MAPTSMN1; SMN2NPC1NFKB1
SCHEMBL4129151 0.80 KDM4E (0.49) GPR119MAPTSMN1; SMN2NPC1NFKB1
SCHEMBL2084476 0.74 CNR1 (0.36) GPR119SMOCNR1CNR2KMT2A
SCHEMBL2085537 0.73 TYK2 (0.37) SMOCNR1CNR2KMT2AMEN1
SCHEMBL2084473 0.71 KDM4E (0.56) GPR119MAPTSMN1; SMN2NPC1NFKB1
SCHEMBL2086167 0.71 ALDH1A1 (0.37) MAPTSMN1; SMN2NPC1RAB9ACNR1
SCHEMBL2083955 0.68 RAB9A (0.51) GPR119MAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD GPR119 2137/4885SMO 2449/4885MAPT 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.